Advertisement
Advertisement
AYTU
AYTU BioPharma, Inc. Common Stock
2.50
USDSponsored
+0.03
+1.21%
May 08, 15:59 UTC -4
Closed
After-Market
2.50
0.00
-0.20%
AYTU Earnings Reports
Positive Surprise Ratio
AYTU beat 21 of 37 last estimates.
57%
Next Report
In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q3 26 (Revenue/ EPS)
$12.29M
/-$0.52
Implied change from Q2 26 (Revenue/ EPS)
-18.93%
/-50.48%
Implied change from Q3 25 (Revenue/ EPS)
-33.37%
/-347.62%
AYTU BioPharma, Inc. Common Stock earnings per share and revenue
On Feb 03, 2026, AYTU reported earnings of -1.05 USD per share (EPS) for Q2 26, missing the estimate of -0.61 USD, resulting in a -71.57% surprise. Revenue reached 15.16 million, compared to an expected 12.42 million, with a 22.12% difference. The market reacted with a -10.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.52 USD, with revenue projected to reach 12.29 million USD, implying an decrease of -50.48% EPS, and decrease of -18.93% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were AYTU BioPharma, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, AYTU BioPharma, Inc. Common Stock reported EPS of -$1.05, missing estimates by -71.57%, and revenue of $15.16M, 22.12% above expectations.
How did the market react to AYTU BioPharma, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -10.31%, changed from $2.62 before the earnings release to $2.35 the day after.
When is AYTU BioPharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for AYTU BioPharma, Inc. Common Stock's next earnings report?
Based on 5
analysts, AYTU BioPharma, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of $12.29M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement